Streetbeat News

Analyst Ratings

PTLO

Baird analyst David Tarantino maintains an Outperform rating on Portillos (NASDAQ:PTLO) but has lowered the price target from $30 to $26.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 3:20 pm

FULC

HC Wainwright & Co. analyst Andrew Fein has reiterated a Neutral rating on Fulcrum Therapeutics (NASDAQ:FULC) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:19 pm

PBYI

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Puma Biotechnology (NASDAQ:PBYI) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:19 pm

ABNB

Mizuho analyst James Lee maintains a Neutral rating on Airbnb (NASDAQ:ABNB) and raises the price target from $145 to $150.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 3:19 pm

SHAK

Baird analyst David Tarantino maintains a Neutral rating on Shake Shack (NYSE:SHAK) and raises the price target from $74 to $78.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 3:19 pm

DVAX

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Dynavax Technologies (NASDAQ:DVAX) and maintained a price target of $27.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:19 pm

CMRX

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Chimerix (NASDAQ:CMRX) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:19 pm

CRIS

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Curis (NASDAQ:CRIS) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:19 pm

APD

Mizuho analyst Christopher Parkinson maintains a 'Buy' rating on Air Products & Chemicals (NYSE:APD) and raises the price target from $322 to $330.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 04, 2023 | 3:18 pm

CLVT

Oppenheimer analyst Owen Lau has maintained an 'Outperform' rating on Clarivate (NYSE:CLVT), but lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 3:18 pm